Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution
Many tumors have well-defined vulnerabilities, thus potentially allowing highly specific and effective treatment. There is a spectrum of actionable genetic alterations which are shared across various tumor types and, therefore, can be targeted by a given drug irrespective of tumor histology. Several...
Main Authors: | Svetlana N. Aleksakhina, Alexander O. Ivantsov, Evgeny N. Imyanitov |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/25/7/4094 |
Similar Items
-
The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair
by: Vilma Pacheco-Barcia, et al.
Published: (2022-06-01) -
The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Giovanni Maria Iannantuono, et al.
Published: (2022-08-01) -
Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis
by: Xianlin Cheng, et al.
Published: (2023-10-01) -
Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
by: Masaya Senda, et al.
Published: (2023-11-01) -
Understanding the Reasons That Lead Young People in Bogota to Identify as Atheist and Agnostic
by: William Mauricio Beltrán, et al.
Published: (2023-06-01)